147 related articles for article (PubMed ID: 32690646)
1. Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.
Chapagain M; Gumbo T; Heysell SK; Srivastava S
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32690646
[TBL] [Abstract][Full Text] [Related]
2. Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease.
Singh S; Gumbo T; Boorgula GD; Shankar P; Heysell SK; Srivastava S
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068722. PubMed ID: 35976006
[TBL] [Abstract][Full Text] [Related]
3. Clofazimine for the Treatment of Mycobacterium kansasii.
Srivastava S; Gumbo T
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844047
[No Abstract] [Full Text] [Related]
4. Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii.
Boorgula GD; Singh S; Shankar P; Gumbo T; Heysell SK; Srivastava S
Tuberculosis (Edinb); 2023 Jan; 138():102289. PubMed ID: 36512853
[TBL] [Abstract][Full Text] [Related]
5. Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.
Srivastava S; Boorgula GD; Wang JY; Huang HL; Howe D; Gumbo T; Heysell SK
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0232021. PubMed ID: 35315686
[TBL] [Abstract][Full Text] [Related]
6. Nouveau short-course therapy and morphism mapping for clinical pulmonary
Srivastava S; Wang JY; Magombedze G; Chapagain M; Huang HL; Deshpande D; Heysell SK; Pasipanodya JG; Gumbo T
Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33558291
[TBL] [Abstract][Full Text] [Related]
7. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease.
Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i48-i53. PubMed ID: 28922809
[TBL] [Abstract][Full Text] [Related]
8. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
Srivastava S; Pasipanodya J; Sherman CM; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2015 Apr; 59(4):2273-9. PubMed ID: 25645830
[TBL] [Abstract][Full Text] [Related]
9. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease.
Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T
J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i30-i35. PubMed ID: 28922807
[TBL] [Abstract][Full Text] [Related]
10. An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.
Srivastava S; Pasipanodya JG; Heysell SK; Boorgula GD; Gumbo T; McShane PJ; Philley JV
J Glob Antimicrob Resist; 2022 Mar; 28():71-77. PubMed ID: 34933140
[TBL] [Abstract][Full Text] [Related]
11. Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.
Deshpande D; Srivastava S; Nuermberger E; Koeuth T; Martin KR; Cirrincione KN; Lee PS; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S342-S348. PubMed ID: 30496456
[TBL] [Abstract][Full Text] [Related]
12. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
Srivastava S; Deshpande D; Nuermberger E; Lee PS; Cirrincione K; Dheda K; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S336-S341. PubMed ID: 30496463
[TBL] [Abstract][Full Text] [Related]
13. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.
Ruth MM; Magombedze G; Gumbo T; Bendet P; Sangen JJN; Zweijpfenning S; Hoefsloot W; Pennings L; Koeken VACM; Wertheim HFL; Lee PS; van Ingen J; Deshpande D
J Antimicrob Chemother; 2019 Jul; 74(7):1952-1961. PubMed ID: 31039251
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tedizolid against the Mycobacterium abscessus complex.
Compain F; Soroka D; Heym B; Gaillard JL; Herrmann JL; Dorchène D; Arthur M; Dubée V
Diagn Microbiol Infect Dis; 2018 Mar; 90(3):186-189. PubMed ID: 29217419
[TBL] [Abstract][Full Text] [Related]
15. Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy.
Deshpande D; Srivastava S; Pasipanodya JG; Gumbo T
Front Pharmacol; 2022; 13():1024608. PubMed ID: 36330086
[No Abstract] [Full Text] [Related]
16. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating
Srivastava S; Cirrincione KN; Deshpande D; Gumbo T
Front Pharmacol; 2020; 11():616294. PubMed ID: 33542690
[No Abstract] [Full Text] [Related]
17. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
Ruth MM; Koeken VACM; Pennings LJ; Svensson EM; Wertheim HFL; Hoefsloot W; van Ingen J
J Antimicrob Chemother; 2020 Mar; 75(3):609-617. PubMed ID: 31886864
[TBL] [Abstract][Full Text] [Related]
18. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study.
Griffith DE; Brown-Elliott BA; Wallace RJ
Clin Infect Dis; 2003 Nov; 37(9):1178-82. PubMed ID: 14557961
[TBL] [Abstract][Full Text] [Related]
19. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
20. Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill.
Gumbo T; Cirrincione K; Srivastava S
J Antimicrob Chemother; 2020 May; 75(5):1212-1217. PubMed ID: 32016429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
